002675 东诚药业
已收盘 05-13 15:00:00
资讯
新帖
简况
东诚药业：蓝纳成证监会备案正在审理中
证券之星 · 05-13 20:52
东诚药业：蓝纳成证监会备案正在审理中
东诚药业（002675）披露回购公司股份进展情况公告，5月6日股价上涨0.23%
证券之星 · 05-06
东诚药业（002675）披露回购公司股份进展情况公告，5月6日股价上涨0.23%
每周股票复盘：东诚药业（002675）股东户数增45.95%，净利升35.19%
证券之星 · 05-03
每周股票复盘：东诚药业（002675）股东户数增45.95%，净利升35.19%
东诚药业（002675）披露2026年一季度报告，4月27日股价下跌1.33%
证券之星 · 04-27
东诚药业（002675）披露2026年一季度报告，4月27日股价下跌1.33%
图解东诚药业一季报：第一季度单季净利润同比增长35.19%
证券之星 · 04-27
图解东诚药业一季报：第一季度单季净利润同比增长35.19%
东诚药业（002675）披露2025年度权益分派实施公告，4月22日股价上涨0.58%
证券之星 · 04-22
东诚药业（002675）披露2025年度权益分派实施公告，4月22日股价上涨0.58%
东诚药业（002675）披露2025年度股东会决议公告，4月15日股价上涨3.1%
证券之星 · 04-15
东诚药业（002675）披露2025年度股东会决议公告，4月15日股价上涨3.1%
股市必读：东诚药业（002675）4月3日收盘跌5.63%，主力净流出419.56万元
证券之星 · 04-07
股市必读：东诚药业（002675）4月3日收盘跌5.63%，主力净流出419.56万元
4月3日东诚药业跌5.63%，银河医药混合A基金重仓该股
证券之星 · 04-03
4月3日东诚药业跌5.63%，银河医药混合A基金重仓该股
东诚药业（002675）披露回购公司股份进展情况公告，4月2日股价上涨5.46%
证券之星 · 04-02
东诚药业（002675）披露回购公司股份进展情况公告，4月2日股价上涨5.46%
3月30日东诚药业（002675）涨停分析：核药放量、管线落地、原料自主驱动
证券之星 · 03-30
3月30日东诚药业（002675）涨停分析：核药放量、管线落地、原料自主驱动
东诚药业(002675)2月28日股东户数2.71万户，较上期增加6.34%
证券之星 · 03-26
东诚药业(002675)2月28日股东户数2.71万户，较上期增加6.34%
东诚药业(002675.SZ)发布2025年度业绩，归母净利润1.96亿元，增长6.42%
智通财经 · 03-25
东诚药业(002675.SZ)发布2025年度业绩，归母净利润1.96亿元，增长6.42%
东诚药业（002675）披露225Ac-LNC1011注射液I期临床试验完成首例参与者入组，3月6日股价上涨3.59%
证券之星 · 03-06
东诚药业（002675）披露225Ac-LNC1011注射液I期临床试验完成首例参与者入组，3月6日股价上涨3.59%
东诚药业最新公告：控股子公司蓝纳成自主研发的225Ac-LNC1011注射液完成首例参与者入组
证券之星 · 03-06
东诚药业最新公告：控股子公司蓝纳成自主研发的225Ac-LNC1011注射液完成首例参与者入组
股市必读：东诚药业（002675）3月4日董秘有最新回复
证券之星 · 03-05
股市必读：东诚药业（002675）3月4日董秘有最新回复
东诚药业（002675）披露回购公司股份进展情况公告，3月2日股价下跌3.08%
证券之星 · 03-02
东诚药业（002675）披露回购公司股份进展情况公告，3月2日股价下跌3.08%
东诚药业（002675）披露为下属公司提供担保的进展公告，2月24日股价上涨1.29%
证券之星 · 02-24
东诚药业（002675）披露为下属公司提供担保的进展公告，2月24日股价上涨1.29%
东诚药业（002675）披露回购公司股份进展情况的公告，2月2日股价下跌1.96%
证券之星 · 02-02
东诚药业（002675）披露回购公司股份进展情况的公告，2月2日股价下跌1.96%
东诚药业：主营业务跨多个医药细分领域
证券之星 · 01-30
东诚药业：主营业务跨多个医药细分领域
加载更多
公司概况
公司名称：
烟台东诚药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2012-05-25
主营业务：
烟台东诚药业集团股份有限公司的主营业务是放射性核素药物、抗凝血肝素类原料药及其下游制剂的生产销售。公司的主要产品是肝素钠原料药、硫酸软骨素、制剂产品、核素药物。
发行价格：
26.00
{"stockData":{"symbol":"002675","market":"SZ","secType":"STK","nameCN":"东诚药业","latestPrice":12.89,"timestamp":1778655819000,"preClose":12.89,"halted":0,"volume":7708298,"delay":0,"changeRate":0,"floatShares":743000000,"shares":825000000,"eps":0.2478,"marketStatus":"已收盘","change":0,"latestTime":"05-13 15:00:00","open":12.87,"high":12.95,"low":12.73,"amount":98893600,"amplitude":0.0171,"askPrice":12.9,"askSize":376,"bidPrice":12.89,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.2478,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778722200000},"marketStatusCode":5,"adr":0,"adjPreClose":12.89,"symbolType":"stock","openAndCloseTimeList":[[1778635800000,1778643000000],[1778648400000,1778655600000]],"highLimit":14.18,"lowLimit":11.6,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":824595705,"isCdr":false,"pbRate":2.48,"roa":"--","peRate":52.017756,"roe":"0.77%","epsLYR":0.2372,"committee":-0.469159,"marketValue":10629000000,"turnoverRate":0.0104,"status":2,"floatMarketCap":9582000000},"requestUrl":"/m/hq/s/002675","defaultTab":"news","newsList":[{"id":"2635778754","title":"东诚药业：蓝纳成证监会备案正在审理中","url":"https://stock-news.laohu8.com/highlight/detail?id=2635778754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635778754?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:52","pubTimestamp":1778676732,"startTime":"0","endTime":"0","summary":"作为公司在二级市场上的长期持股小股东，第一：请问一下子公司蓝纳成港股何时上市？东诚药业回复：您好，蓝纳成证监会备案正在审理中，同时蓝纳成香港 IPO 材料正在更新中，递交后公司将会及时披露，请您关注相关公告；锝[99mTc]替曲膦注射液是诊断用核素药物，主要用于SPECT心肌灌注显像剂，目前暂无延伸其他适应症；18F-APN-1607 产品正在按照 CDE 要求补充相关临床实验，公司正在积极推进研发进度，争取早日上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300042456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633134547","title":"东诚药业（002675）披露回购公司股份进展情况公告，5月6日股价上涨0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633134547","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633134547?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:38","pubTimestamp":1778078298,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，东诚药业报收于13.02元，较前一交易日上涨0.23%，最新总市值为107.36亿元。该股当日开盘12.99元，最高13.24元，最低12.91元，成交额达1.43亿元，换手率为1.47%。近日，烟台东诚药业集团股份有限公司披露《关于回购公司股份进展情况的公告》。公告显示，公司于2025年12月31日召开董事会，审议通过以集中竞价方式回购股份的方案，拟使用自有及自筹资金回购股份，用于股权激励和/或员工持股计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600040008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632674302","title":"每周股票复盘：东诚药业（002675）股东户数增45.95%，净利升35.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632674302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632674302?lang=zh_cn&edition=full","pubTime":"2026-05-03 02:50","pubTimestamp":1777747823,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，东诚药业报收于12.99元，较上周的13.55元下跌4.13%。本周，东诚药业4月28日盘中最高价报13.75元。股本股东变化截至2026年3月31日，东诚药业股东户数为3.95万户，较2月28日增加1.25万户，增幅达45.95%。公司公告汇总2026年第一季度，东诚药业实现营业收入626,367,330.36元，同比下降8.82%；归属于上市公司股东的净利润为33,435,403.61元，同比增长35.19%；扣除非经常性损益后的净利润为29,927,987.91元，同比增长56.36%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630390898","title":"东诚药业（002675）披露2026年一季度报告，4月27日股价下跌1.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630390898","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630390898?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:11","pubTimestamp":1777299103,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，东诚药业报收于13.37元，较前一交易日下跌1.33%，最新总市值为110.25亿元。近日，东诚药业披露《2026年一季度报告》。报告显示，2026年第一季度，公司实现营业收入626,367,330.36元，同比下降8.82%；归属于上市公司股东的净利润为33,435,403.61元，同比增长35.19%；扣除非经常性损益后的净利润为29,927,987.91元，同比增长56.36%。基本每股收益0.0405元，同比增长35.00%。总资产为9,178,967,785.06元，较上年度末下降0.49%；归属于上市公司股东的所有者权益为4,286,341,387.78元，较上年度末下降1.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700045798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630362099","title":"图解东诚药业一季报：第一季度单季净利润同比增长35.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630362099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630362099?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:12","pubTimestamp":1777284775,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业2026年一季报显示，一季度公司主营收入6.26亿元，同比下降8.82%；归母净利润3343.54万元，同比上升35.19%；扣非净利润2992.8万元，同比上升56.36%；负债率41.12%，投资收益147.04万元，财务费用4225.91万元，毛利率53.13%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700033750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629047023","title":"东诚药业（002675）披露2025年度权益分派实施公告，4月22日股价上涨0.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629047023","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629047023?lang=zh_cn&edition=full","pubTime":"2026-04-22 22:16","pubTimestamp":1776867375,"startTime":"0","endTime":"0","summary":"截至2026年4月22日收盘，东诚药业报收于13.94元，较前一交易日上涨0.58%，最新总市值为114.95亿元。近日，烟台东诚药业集团股份有限公司发布《2025年度权益分派实施公告》。公告显示，公司2025年度权益分派方案为：以公司现有总股本824,595,705股剔除回购股份6,336,799股后的818,258,906股为基数，向全体股东每10股派0.806195元现金（含税）。本次权益分派股权登记日为2026年4月28日，除权除息日为2026年4月29日。本次分派后，回购股份价格上限由18.00元/股调整为17.92元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200054438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627233387","title":"东诚药业（002675）披露2025年度股东会决议公告，4月15日股价上涨3.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627233387","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627233387?lang=zh_cn&edition=full","pubTime":"2026-04-15 22:28","pubTimestamp":1776263294,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，东诚药业报收于14.65元，较前一交易日上涨3.1%，最新总市值为120.8亿元。该股当日开盘14.42元，最高14.66元，最低14.1元，成交额达6亿元，换手率为5.59%。近日，东诚药业发布《2025年度股东会决议公告》。公告显示，公司于2026年4月15日召开2025年度股东会，审议通过了《2025年度董事会工作报告》《2025年度报告及其摘要》《2025年度财务决算报告》《2025年度利润分配预案》等议案。出席会议股东代表股份占总股本32.2830%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500043236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625060146","title":"股市必读：东诚药业（002675）4月3日收盘跌5.63%，主力净流出419.56万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2625060146","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625060146?lang=zh_cn&edition=full","pubTime":"2026-04-07 03:32","pubTimestamp":1775503933,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，东诚药业报收于14.58元，下跌5.63%，换手率6.08%，成交量45.22万手，成交额6.66亿元。来自交易信息汇总：前10个交易日主力资金累计净流入1.27亿元，期间股价累计上涨11.01%。交易信息汇总股价提醒4月3日东诚药业收盘报14.58元，跌5.63%，当日成交4522万元。资金流向4月3日主力资金净流出419.56万元，占总成交额0.63%；游资资金净流入979.84万元，占总成交额1.47%；散户资金净流出560.27万元，占总成交额0.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700002267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624183655","title":"4月3日东诚药业跌5.63%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624183655","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624183655?lang=zh_cn&edition=full","pubTime":"2026-04-03 16:15","pubTimestamp":1775204103,"startTime":"0","endTime":"0","summary":"证券之星消息，4月3日东诚药业跌5.63%，收盘报14.58元，换手率6.08%，成交量45.22万手，成交额6.66亿元。重仓东诚药业的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.29亿元，最新净值0.6285，较上一交易日下跌0.03%，近一年上涨18.38%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300031235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK1574","BK0239","BK1161","BK1515","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624073195","title":"东诚药业（002675）披露回购公司股份进展情况公告，4月2日股价上涨5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624073195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624073195?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:16","pubTimestamp":1775139380,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘，东诚药业报收于15.45元，较前一交易日上涨5.46%，最新总市值为127.4亿元。该股当日开盘14.51元，最高15.48元，最低14.4元，成交额达10.34亿元，换手率为9.25%。公司于近日披露《关于回购公司股份进展情况的公告》。本次回购符合相关法规及公司回购方案的规定。公司将在回购期限内继续实施回购计划，并及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200042194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623939263","title":"3月30日东诚药业（002675）涨停分析：核药放量、管线落地、原料自主驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2623939263","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623939263?lang=zh_cn&edition=full","pubTime":"2026-03-30 15:41","pubTimestamp":1774856488,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业3月30日涨停收盘，收盘价14.48元。今日东诚药业涨停的可能因素有：核药业务成第一大收入来源；氟[18F]思睿肽完成III期临床并递交NDA，3款创新核药进入II期、1款进入III期；上游关键阿尔法同位素实现国产毫居里级量产，打破进口依赖；2025年扣非净利同比大增126.51%，经营现金流净额同比+101.9%；叠加礼来与英硅智能达成27.5亿美元AI制药合作引发创新药板块集体走强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000015791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622752858","title":"东诚药业(002675)2月28日股东户数2.71万户，较上期增加6.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622752858","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622752858?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:14","pubTimestamp":1774516469,"startTime":"0","endTime":"0","summary":"证券之星消息，近日东诚药业披露，截至2026年2月28日公司股东户数为2.71万户，较12月31日增加1616.0户，增幅为6.34%。在化学制药行业个股中，东诚药业股东户数低于行业平均水平，截至2月28日，化学制药行业平均股东户数为3.45万户。从股价来看，2025年12月31日至2026年2月28日，东诚药业区间跌幅为3.2%，在此期间股东户数增加1616.0户，增幅为6.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600030781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622502075","title":"东诚药业(002675.SZ)发布2025年度业绩，归母净利润1.96亿元，增长6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622502075","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622502075?lang=zh_cn&edition=full","pubTime":"2026-03-25 20:21","pubTimestamp":1774441283,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业 发布2025年年度报告，该公司营业收入为27.41亿元，同比减少4.46%。归属于上市公司股东的净利润为1.96亿元，同比增长6.42%。基本每股收益为0.2372元。报告期内，核药业务板块销售收入11.36亿元，同比增长12.21%，其中重点产品18F-FDG实现营业收入4.98亿元，同比增长18.35%，主要原因为销量增加;云克注射液实现营业收入2.27亿元，同比下降1.55%;锝标记相关药物实现营业收入1.21亿元，同比增长21.42%。此外，拟向全体股东每10股派发现金红利0.80元(含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东诚药业(002675.SZ)发布2025年度业绩，归母净利润1.96亿元，增长6.42%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617763521","title":"东诚药业（002675）披露225Ac-LNC1011注射液I期临床试验完成首例参与者入组，3月6日股价上涨3.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617763521","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617763521?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:28","pubTimestamp":1772807302,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，东诚药业报收于12.69元，较前一交易日上涨3.59%，最新总市值为104.64亿元。该股当日开盘12.26元，最高12.76元，最低12.22元，成交额达1.35亿元，换手率为1.44%。近日，烟台东诚药业集团股份有限公司控股子公司烟台蓝纳成生物技术股份有限公司自主研发的225Ac-LNC1011注射液I/II期临床试验完成首例参与者入组。本次临床试验旨在评价药物在患者中的安全性、耐受性、药代动力学及初步有效性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600040346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617687498","title":"东诚药业最新公告：控股子公司蓝纳成自主研发的225Ac-LNC1011注射液完成首例参与者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687498","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617687498?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:10","pubTimestamp":1772799054,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，公司控股子公司蓝纳成研发的225Ac-LNC1011注射液I/II期临床完成首例参与者入组，该药物为靶向PSMA的放射性体内治疗药物，拟用于治疗PSMA阳性的转移性去势抵抗性前列腺癌（mCRPC）患者。目前国内外暂无同核素产品上市。药品研发周期长，存在不确定性，敬请投资者谨慎决策。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600036273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617571975","title":"股市必读：东诚药业（002675）3月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2617571975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617571975?lang=zh_cn&edition=full","pubTime":"2026-03-05 01:02","pubTimestamp":1772643739,"startTime":"0","endTime":"0","summary":"截至2026年3月4日收盘，东诚药业报收于12.24元，下跌2.86%，换手率1.22%，成交量9.1万手，成交额1.13亿元。投资者： 董秘您好.截止2月28日公司股东人数是多少？公司股东人数在定期报告中予以披露，如确需查询非定期报告时点的股东人数，您可持个人或机构有效证件、股东账户卡、持股证明到公司办公地进行查询，或将该等有效证明文件、查询要求及联系方式发至邮箱，我们将在核实您的股东身份信息后尽快回复您，如有不明之处，可电话咨询。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500000583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616355441","title":"东诚药业（002675）披露回购公司股份进展情况公告，3月2日股价下跌3.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616355441?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:50","pubTimestamp":1772463029,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，东诚药业报收于12.89元，较前一交易日下跌3.08%，最新总市值为106.29亿元。该股当日开盘13.17元，最高13.17元，最低12.76元，成交额达1.61亿元，换手率为1.67%。近日，烟台东诚药业集团股份有限公司披露《关于回购公司股份进展情况的公告》。公告显示，公司于2025年12月31日召开董事会，审议通过以集中竞价方式回购股份的方案，拟使用自有及自筹资金回购股份，用于股权激励和/或员工持股计划。回购符合相关规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613138737","title":"东诚药业（002675）披露为下属公司提供担保的进展公告，2月24日股价上涨1.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613138737","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613138737?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:24","pubTimestamp":1771932245,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，东诚药业报收于13.37元，较前一交易日上涨1.29%，最新总市值为110.25亿元。近日，东诚药业披露《关于为下属公司提供担保的进展公告》。本次担保事项已经公司第六届董事会第九次会议和2024年度股东大会审议通过，属于公司2025年度对子公司及其下属公司担保额度预计范围内。截至公告日，公司实际对外担保余额为75,200万元，占公司2024年经审计净资产的16.78%，无逾期担保、诉讼等情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400039067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608185767","title":"东诚药业（002675）披露回购公司股份进展情况的公告，2月2日股价下跌1.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608185767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608185767?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:56","pubTimestamp":1770026178,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，东诚药业报收于13.5元，较前一交易日下跌1.96%，最新总市值为111.32亿元。该股当日开盘13.69元，最高13.86元，最低13.48元，成交额达1.54亿元，换手率为1.52%。近日，东诚药业发布《关于回购公司股份进展情况的公告》。公告指出，本次回购符合相关法规及公司既定方案，公司未在禁止期间回购股票，委托价格和交易时段均符合监管要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200026700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607606375","title":"东诚药业：主营业务跨多个医药细分领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2607606375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607606375?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:03","pubTimestamp":1769734989,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业(002675)01月29日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司有用于防预和治疗病毒相关药物吗？东诚药业回复：您好，公司的主要业务包括核医药业务、原料药业务板块和制剂业务板块，主营业务跨多个医药细分领域，覆盖放射性核素药物全链条产业、抗凝血肝素类原料药的生产销售及其下游制剂延伸扩展。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000008008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","002675","BK1161","09939","159938","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778692895562,"stockEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.063},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.173},{"period":"1year","weight":-0.0823},{"period":"ytd","weight":-0.0562}],"compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0637},{"period":"3month","weight":0.0263},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.2571},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"烟台东诚药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"39547人(较上一季度增加45.95%)","perCapita":"18797股","listingDate":"2012-05-25","address":"山东省烟台市福山区经济技术开发区长白山路7号","registeredCapital":"82459万元","survey":" 烟台东诚药业集团股份有限公司的主营业务是放射性核素药物、抗凝血肝素类原料药及其下游制剂的生产销售。公司的主要产品是肝素钠原料药、硫酸软骨素、制剂产品、核素药物。","listedPrice":26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东诚药业,002675,东诚药业股票,东诚药业股票老虎,东诚药业股票老虎国际,东诚药业行情,东诚药业股票行情,东诚药业股价,东诚药业股市,东诚药业股票价格,东诚药业股票交易,东诚药业股票购买,东诚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}